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Abstract
Background
Although viruses are known to be the second most common etiological factor in community-
acquired pneumonia (CAP), the respiratory viral profile of the patients with healthcare-asso-
ciated pneumonia (HCAP) has not yet been elucidated. We investigated the prevalence and
the clinical impact of respiratory virus infection in adult patients with HCAP.
Methods
Patients admitted with HCAP or CAP, between January and December 2016, to a tertiary
referral hospital in Korea, were prospectively enrolled, and virus identification was per-
formed using reverse-transcription polymerase chain reaction (RT-PCR).
Results
Among 452 enrolled patients (224 with HCAP, 228 with CAP), samples for respiratory viruses
were collected from sputum or endotracheal aspirate in 430 (95.1%) patients and from naso-
pharyngeal specimens in 22 (4.9%) patients. Eighty-seven (19.2%) patients had a viral infec-
tion, and the proportion of those with viral infection was significantly lower in the HCAP than
in the CAP group (13.8% vs 24.6%, p = 0.004). In both the HCAP and CAP groups, influenza
A was the most common respiratory virus, followed by entero-rhinovirus. The seasonal distri-
butions of respiratory viruses were also similar in both groups. In the HCAP group, the viral
infection resulted in a similar length of hospital stay and in-hospital mortality as viral–bacterial
coinfection and bacterial infection, and the CAP group showed similar results.
Conclusions
The prevalence of viral infection in patients with HCAP was lower than that in patients with
CAP, and resulted in a similar prognosis as viral–bacterial coinfection or bacterial infection.
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Introduction
Patients increasingly receive treatment at facilities other than hospitals, including long-term
health care facilities, due to the rapidly increasing aged population, who more often have
chronic diseases [1, 2] Pneumonia occurring prior to hospital admission in patients who have
had recent contact with health systems is termed healthcare-associated pneumonia (HCAP)
[3–5]. These patients are believed to be at increased risk for infection with multidrug-resistant
(MDR) organisms [3, 4], and is of particular concern in HCAP patients. However, recent stud-
ies have indicated that many patients defined as having HCAP were not infected with MDR
pathogens [6–10]. Even after excluding MDR pathogens, substantial differences in the etiologi-
cal profile between community-acquired pneumonia (CAP) and HCAP groups have been
noted in recent studies [11, 12], indicating that HCAP settings might present unique risks of
pneumonia.
The incidence of viral pneumonia has increased during the past decade [13]. In part, this
apparent increase reflects improved diagnostic techniques, including polymerase chain reac-
tion (PCR) [13]. Over the last decade, several studies have used PCR to establish the impor-
tance of viruses in the etiology of CAP, and have consistently demonstrated viruses to be the
second most common etiological factor, accounting for 13–50% of diagnosed cases [7, 11, 13–
21]. In a recent systematic review and meta-analysis of viral CAP, no significant association
between viral infection and increased mortality was observed, but mortality was increased in
patients with a bacterial–viral coinfection [22]. However, its clinical implications are debatable,
because most studies performed PCR using nasopharyngeal or oropharyngeal swabs [22],
which might yield a negative result in patients with lower respiratory tract viral infection [11,
23].
Unlike CAP, the viral profile and the clinical implications thereof in HCAP are not well
studied. Therefore, we performed this prospective study 1) to investigate the role of viral infec-
tion in patients with HCAP and CAP, using all available adequate respiratory specimens from
our institution, and 2) to identify the seasonal variation in both groups of patients.
Materials and methods
Study design and patients
This study was conducted at a tertiary referral hospital in Republic of Korea. All adult patients,
who were admitted to the hospital with HCAP or CAP from January 1 to December 31, 2016,
were prospectively recruited after providing written informed consent. Patients were excluded
from the study if they had pneumonia related to witnessed aspiration during eating or vomit-
ing, obstructive pneumonia related to airway obstruction by a tumor, hospital-acquired
(HAP), or ventilator-associated pneumonia (VAP). Patients who did not undergo any micro-
biological studies before antibiotic administration, who received any form of antibiotics for
more than 24 hrs prior to our hospital or who refused to participate in this study were also
excluded. If a patient had multiple pneumonia episodes within the study period, only the first
pneumonia episode was recorded. The study was approved by the Institutional Review Board
and Ethics Committee of Seoul National University Bundang Hospital (SNUBH) (IRB No. B-
1511-324-306) and was conducted in compliance with the Declaration of Helsinki.
Definitions
Pneumonia was defined as the presence of new infiltrates on chest X-rays along with other sug-
gestive signs and symptoms: cough, sputum, fever, chills, dyspnea, pleuritic chest pain, distur-
bance of consciousness, and crackles [3, 24]. The patients with HCAP had to fulfill any of the
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following: received intravenous therapy at home; received wound care or nursing care through
a health care agency; or had intravenous medical therapy in the 30 days before pneumonia; or
attended a hemodialysis clinic; or received intravenous chemotherapy in the 30 days before
pneumonia; or admitted to a hospital for 2 or more days in the 90 days before pneumonia; or
resided in a nursing home or a long-term care facility. Patients were classified into the CAP if
they did not fit the criteria for HCAP.
Microbiological studies
Microbiological samples were collected within 48 hr after diagnosis of pneumonia. Microbio-
logical studies included 2 or 3 sets of blood cultures and sputum or endotracheal aspirates for
Gram staining and culturing. Urinary antigen tests for Streptococcus pneumoniae (Binax Inc.,
Portland, ME) and PCR tests for Mycoplasma pneumoniae (in-house developed nucleic acid
sequence based amplification) were performed when indicated by the attending physician.
Bronchoalveolar lavage (BAL) fluid or thoracentesis was conducted if indicated for the diagno-
sis. All patients were tested for respiratory virus by multiplex reverse-transcription PCR
(RT-PCR), using all available respiratory specimens. If the patients had no sputum, RT-PCR
was conducted on a nasopharyngeal specimen. Respiratory virus multiplex RT-PCR was per-
formed according to the xTAG respiratory viral panel (RVP) assay product insert instructions
(Luminex Molecular Diagnostics, Toronto, Canada). We considered that pneumonia was
caused by a specific virus if respiratory viruses were detected in acceptable respiratory samples
by RT-PCR [25]. Respiratory samples were considered acceptable when more than 25 poly-
morphonuclear cells and fewer than 10 squamous squamous epithelial cells were observed
under low-power magnification were observed under low-power magnification [26–30].
Statistical analysis
Unless otherwise specified, results are expressed as mean (standard deviation, SD) or median
(range) for continuous variables and as percentage for categorical variables. Student’s t-test
was used to compare continuous variables; chi-square or Fisher’s exact tests were used to com-
pare categorical variables. Variables with p< 0.1 in univariate analysis were entered into a
multivariate logistic regression analysis to identify independent predictors of mortality. Unless
otherwise noted, all tests were 2-sided and performed at the 0.05 significance level. Analyses
were performed using SPSS 20.0 (IBM Corp., Armonk, NY, USA).
Results
Baseline characteristics
Among 2755 patients who visited the emergency department due to pneumonia during the
1-year study period, 507 patients were diagnosed with HCAP or CAP. Fifty-five patients were
excluded from the study because the microbiological specimens obtained prior to antibiotic
administration were unacceptable (n = 37), or due to overlapping participation (n = 9); absence
of RT-PCR results (n = 6); or withdrawal of informed consent (n = 3) (Fig 1). The baseline char-
acteristics of 452 patients (HCAP: 224 patients; CAP: 228 patients) are shown in Table 1. Con-
ventional microbiological studies, including blood culturing and sputum or endotracheal
aspirate Gram staining and culturing, were conducted in all enrolled patients before or just after
administration of antibiotics (within 1 hr). BAL was conducted in 67 (14.8%) patients and addi-
tional diagnostic thoracentesis was performed in 19 (4.2%) patients. The proportions of patients
who underwent BAL and thoracentesis were similar in the CAP and HCAP groups (BAL, 12.3%
vs 17.4%, p = 0.125; thoracentesis, 3.5% vs 4.9%, p = 0.458). Pathogens related to pneumonia
Viral infection in HCAP and CAP
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were identified in 235 (52.0%) patients. Among them, 107 (23.7%) patients had bacterial pneu-
monia, while 87 (19.2%) patients had viral, and 41 (9.1%) patients had viral–bacterial coinfec-
tion. (S1 Table).
Viral profiles in pneumonia
Among the 452 enrolled patients, 430 (95.1%) patients were tested for respiratory viruses in
sputum or endotracheal aspirates. The remaining 22 (4.9%) patients underwent RT-PCR on
nasopharyngeal specimens. Additionally, BAL fluid RT-PCR was performed in 16 (3.5%)
patients, and 4 (0.9%) patients underwent pleural effusion RT-PCR. Fifty-four (23.7%) of the
patients with HCAP were found to have a viral infection; 31 (13.8%) patients had a pure viral
infection and 23 (10.3%) patients had a viral–bacterial coinfection. In the CAP group, 74
(32.5%) patients had a viral infection, and the viral infection rate and viral–bacterial coinfec-
tion rates were 24.6% and 7.9% respectively. The viral infection rate was significantly lower in
the HCAP patients than in the CAP patients, irrespective of whether viral–bacterial infections
were included (viral infection with viral–bacterial coinfection, p = 0.049, viral infection only,
p = 0.004). The respiratory viruses identified are summarized in Table 2. In both HCAP and
CAP groups, influenza A was the most common respiratory virus, followed by entero-rhinovi-
rus. The general viral profile of patients with HCAP and CAP were similar, except for influ-
enza A and adenovirus, which were higher in the CAP group than the HCAP (p = 0.040 and
Fig 1. Flow chart of patient enrollment into the study. Abbreviations: CAP, community-acquired pneumonia; HAP, hospital-acquired pneumonia;
HCAP, healthcare-associated pneumonia; VAP, ventilator-associated pneumonia; RT-PCR, reverse-transcription polymerase chain reaction.
https://doi.org/10.1371/journal.pone.0192893.g001
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Table 1. Baseline characteristics of enrolled patients.
Total (n = 452) HCAP (n = 224) CAP (n = 228) P value
Male sex 279 (62.7) 142 (63.4) 137 (60.1) 0.470
Age, years 70.5 (15.0) 72.4 (11.5) 68.6 (17.6) 0.006
BMI, kg/m2 21.8 (4.2) 21.1 (4.1) 22.4 (4.3) 0.002
Ever-smoker 120 (26.5) 49 (21.9) 71 (31.1) 0.026
Alcoholism 52 (11.5) 16 (7.1) 36 (15.8) 0.004
In the army 7 (1.5) 0 (0.0) 7 (3.1) 0.015
ECOG 3 187 (41.4) 123 (54.9) 64 (28.1) < 0.001
Comorbidities
Diabetes mellitus (any type) 129 (28.5) 73 (32.6) 56 (24.6) 0.063
Hypertension 214 (47.3) 111 (49.6) 103 (45.2) 0.351
Chronic liver disease 14 (3.1) 8 (3.6) 6 (2.6) 0.564
Chronic kidney disease 35 (7.7) 21 (9.4) 14 (6.1) 0.198
Ischemic heart disease 74 (16.4) 46 (20.5) 28 (12.3) 0.018
Congestive heart failure 18 (4.0) 10 (4.5) 8 (3.5) 0.603
Chronic lung disease 109 (24.1) 35 (15.6) 74 (32.5) < 0.001
Bronchiectasis 25 (5.5) 5 (2.2) 10 (0.4) 0.002
COPD 62 (13.7) 23 (10.3) 39 (17.1) 0.035
Bronchial asthma 38 (8.4) 6 (2.7) 32 (14.0) < 0.001
Interstitial lung disease 7 (1.5) 3 (1.3) 4 (1.8) 1.000
Solid cancer 85 (18.8) 66 (29.5) 19 (8.3) < 0.001
Hematologic malignancy 47 (10.4) 33 (14.7) 14 (6.1) 0.003
Aspiration pneumonia 85 (18.8) 62 (27.7) 23 (10.1) < 0.001
Pneumonia severity index 105.6 (36.3) 123.0 (29.8) 88.3 (34.0) < 0.001
CURB-65 2 234 (51.8) 137 (61.2) 97 (42.5) < 0.001
CURB-65 3 81 (17.9) 50 (22.3) 31 (13.6) 0.016
qSOFA 2 57 (12.6) 46 (20.5) 11 (4.8) < 0.001
Direct sub-ICU admission 35 (7.7) 24 (10.7) 11 (4.8) 0.019
Direct ICU admission 27 (6.0) 16 (7.1) 11 (4.8) 0.298
Initial Sepsis 6 (1.3) 4 (1.8) 2 (0.9) 0.399
Initial septic shock 11 (2.4) 8 (3.6) 3 (1.3) 0.120
Initial laboratory findings
White blood cells /mm3 11.8 (8.3) 11.1 (6.5) 12.6 (9.8) 0.058
Hematocrit, % 36.1 (6.1) 33.9 (6.4) 38.3 (5.1) < 0.001
Platelets, 103/mm3 222.6 (110.9) 218.4 (117.7) 216.7 (103.9) 0.425
BUN, mg/dL 24.5 (19.7) 27.3 (20.9) 21.8 (18.0) 0.003
Creatinine, mg/dL 1.3 (1.3) 1.3 (1.3) 1.2 (1.3) 0.529
CRP, mg/dL 11.8 (7.8) 12.1 (7.6) 11.6 (7.9) 0.535
Procalcitonin (n = 205), ng/mL 0.5 (0.0–32.1) 1.5 (0.1–32.1) 0.5 (0.0–13.3) 0.014
Pro BNP (n = 203), pg/mL 660.7 (10.5–35000) 779.7 (143.5–22663.4) 400.3 (10.5–35000) 0.315
Lactic acid (n = 302) 1.4 (0.2–5.9) 1.1 (0.2–5.9) 1.5 (0.6–4.1) 0.019
D-dimer (n = 323), μg/mL 2.0 (0.4–20.0) 2.4 (0.4–20.0) 1.7 (0.4–20.0) 0.005
Note: Significant differences between patients with CAP and HCAP were tested using chi-square, or Fisher’s exact test. Data are mean (SD), number (%) patients, or
median (range).
Abbreviations: BUN, blood urea nitrogen; BNP, brain natriuretic peptide; BMI, body mass index; CAP, community-acquired pneumonia; COPD, chronic obstructive
pulmonary disease; CRP, C-reactive protein; ECOG, eastern cooperative oncology group; HCAP, healthcare-associated pneumonia; ICU, intensive care unit; qSOFA,
quick sequential organ failure assessment
https://doi.org/10.1371/journal.pone.0192893.t001
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p = 0.001, respectively). Among the 16 patients who underwent BAL fluid RT-PCR, 14 (87.5%)
patients demonstrated the same results as those obtained from sputum RT-PCR. In the
remaining 2 patients, no virus was identified by sputum RT-PCR, but respiratory syncytial
virus and influenza A were identified, respectively, in BAL fluid RT-PCR. One of 4 patients
had a positive viral result on pleural effusion RT-PCR and this was identical to the endotra-
cheal aspirate RT-PCR. The viral profiles, according to respiratory specimens, are shown in
S2 Table.
Table 2. Profile of pathogens identified in patients with HCAP or CAP.
Total (n = 235) HCAP (n = 134) CAP (n = 101) P value
Viral
Influenza virus A 44 (18.7) 19 (14.2) 25 (24.8) 0.040
Entero-Rhinovirus 29 (12.3) 15 (11.2) 14 (13.9) 0.538
Human metapneumovirus 14 (6.0) 5 (3.7) 9 (8.9) 0.097
Respiratory syncytial virus 14 (6.0) 5 (3.7) 9 (8.9) 0.097
Parainfluenza virus 11 (4.7) 7 (5.2) 4 (4.0) 0.650
Parainfluenza virus 1 4 (1.7) 2 (1.5) 2 (2.0) 1.000
Parainfluenza virus 2 2 (0.9) 2 (1.5) 0 (0.0) 0.508
Parainfluenza virus 3 5 (2.1) 3 (2.2) 2 (2.0) 1.000
Adenovirus 8 (3.4) 0 (0.0) 8 (7.9) 0.001
Coronavirus 7 (3.0) 5 (3.7) 2 (2.0) 0.702
Coronavirus 229E 1 (0.4) 1 (0.7) 0 (0.0) 1.000
Coronavirus NL63 1 (0.4) 0 (0.0) 1 (1.0) 0.430
+Coronavirus OC43 5 (2.1) 4 (3.0) 1 (1.0) 0.394
Influenza virus B 5 (2.1) 1 (0.7) 4 (4.0) 0.168
Bacterial
Multi-bacterial 27 (11.5) 21 (15.7) 6 (5.9) 0.021
Multidrug-resistant 39 (16.6) 35 (26.1) 4 (4.0) < 0.001
Streptococcus pneumoniae 40 (17.0) 22 (16.4) 18 (17.8) 0.777
Klebsiella pneumoniae 32 (13.6) 22 (16.4) 10 (9.9) 0.149
Pseudomonas aeruginosa 24 (10.2) 20 (14.9) 4 (4.0) 0.006
MRSA 21 (8.9) 18 (13.4) 3 (3.0) 0.005
MSSA 16 (6.8) 8 (6.0) 8 (7.9) 0.557
Escherichia coli 12 (5.1) 10 (7.5) 2 (2.0) 0.059
Haemophilus influenzae 8 (3.4) 7 (5.2) 1 (1.0) 0.142
Enterobacter cloacae 6 (2.6) 3 (2.2) 3 (3.0) 1.000
Acinetobacter baumannii 6 (2.6) 5 (3.7) 1 (1.0) 0.241
Serratia marcescens 3 (1.3) 3 (2.2) 0 (0.0) 0.553
Mycoplasma pneumoniae 2 (0.9) 0 (0.0) 2 (2.0) 0.103
Stenotrophomonas maltophilia 2 (0.9) 2 (1.5) 0 (0.0) 0.218
Citrobacter freundii 1 (0.4) 1 (0.7) 0 (0.0) 1.000
Others
Pneumocystis jirovecii 2 (0.9) 2 (1.5) 0 (0.0) 0.508
Note: Significant differences between patients with CAP and HCAP were tested using chi-square, or Fisher’s exact test. Data are mean (SD), number (%) patients, or
median (range).
Abbreviations: CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; MRSA, Methicillin-resistant Staphylococcus aureus; MSSA,
Methicillin-sensitive Staphylococcus aureus
https://doi.org/10.1371/journal.pone.0192893.t002
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Bacterial profiles in pneumonia
More than half of the patients (64.9%) with HCAP received antibiotics at the healthcare facili-
ties and 21 (20.8%) patients with CAP received any form of antibiotics prior to our hospital. In
contrast to viral infection, the proportion of bacterial pneumonia was significantly higher in
patients with HCAP than in those with CAP (35.7% vs 11.8%, p< 0.001). Table 2 shows the
bacterial pathogens in patients with HCAP or CAP. Pseudomonas aeruginosa and methicillin-
resistant Staphylococcus aureus (MRSA) were more frequently observed in HCAP than in CAP
patients (p = 0.006 and p = 0.005, respectively). The proportion of multi-bacterial and multi-
drug-resistant (MDR) bacterial infection was also higher in the HCAP than CAP group
(p = 0.021 and p< 0.001, respectively). Empirical antimicrobial treatment regimens for HCAP
or CAP are summarized in S3 Table.
Seasonal distribution of pneumonia
Fig 2 shows the monthly distribution of viral and bacterial infection. In the HCAP group, bac-
terial infections were predominant during all 4 seasons, and were more common from Febru-
ary to April. The seasonal variation curve of viral infections was similar to that in the CAP
group, but with a tendency to lag 1 month behind that in the CAP group. Fig 3 shows the dis-
tribution of each virus. Generally, the viral seasonal distribution in the HCAP group was simi-
lar to that in the CAP group, except for adenovirus and human metapneumovirus. Of the 44
patients with influenza pneumonia, more than half (63.6%) had a history of influenza
vaccination.
Outcomes of pneumonia and predictors of mortality
The median length of hospital stay (LOS) was 8.2 (range: 0.0–120.0) days. Patients with HCAP
had a significantly longer LOS than did patients with CAP (7.1 vs. 9.8 days, p = 0.009). Thirty-
one (6.9%) patients died in the hospital; the HCAP group had a higher mortality than did the
CAP group (6.7% vs. 3.5%, p = 0.004). After hospitalization, 344 (76.15) returned home and 76
(16.8%) patients were transferred to a nursing care home. When each group was considered
separately, the CAP patients with viral infection, or viral–bacterial coinfection, or bacterial
infection had a similar hospital LOS (p = 0.330), in-hospital mortality (p = 0.269), and transfer
rate to a nursing home (p = 0.191). Likewise, viral infection did not affect the clinical prognosis
in the HCAP group, including the hospital LOS (p = 0.377), mortality (p = 0.930), and dis-
charge rate to a nursing home (p = 0.184). Multivariate analysis revealed that MRSA infection
(OR 8.79, 95% CI 1.474–52.360, p = 0.017), BUN (OR 1.04, 95% CI 1.012–1.072, p = 0.006),
and lactic acid (OR 1.18, 95% CI 1.012–1.372, p = 0.034) were independent predictors of in-
hospital mortality in patients with HCAP or CAP. Moreover, MRSA infection was the stron-
gest predictor of in-hospital mortality in HCAP patients (OR 10.0, 95% CI 1.331–75.619,
p = 0.025).
Discussion
In this study, we investigated the microbiological profile of patients with HCAP, focusing on
viral infections. To date, only limited studies have evaluated the viral profile of patients with
HCAP [11, 31, 32]. However, these studies only included patients with severe pneumonia
requiring ICU care focusing on the CAP, which involved only a limited number of HCAP
patients [32]. Furthermore, they did not strictly control the respiratory sampling time and did
not specified whether the patients received antibiotics and how long they received the antibiot-
ics prior to admission [31]. Lastly, only limited respiratory specimens were used for detection
Viral infection in HCAP and CAP
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Fig 2. Monthly distribution of respiratory viral or bacterial pneumonia. The x-axis shows each month and the y-
axis shows the number of observed pneumonia events. The number of viral and bacterial pneumonia events in each
month. (upper panel: all CAP and HCAP patients, middle panel: CAP patients only; and lower panel: HCAP patients
only).
https://doi.org/10.1371/journal.pone.0192893.g002
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of respiratory viruses, mainly nasopharyngeal swab [31, 32]. Therefore, the general trend and
microbiological profile in HCAP remained unclear. In the present study, we evaluated the role
of respiratory viruses in patients with mild to severe HCAP, in comparison to that in patients
with CAP, using all available respiratory specimens including sputum or endotracheal aspirate,
BAL fluid or even pleural effusion. Unlike previous studies [31], microbiological results
showed some differences in both groups. The overall viral infection rates were lower in the
HCAP group (23.7%) than in the CAP group (32.5%). Most importantly, influenza A viral
infection was significantly lower in the patients with HCAP than those with CAP (p = 0.040).
There are several plausible explanations for this. In the previous multicenter study, bronchial
asthma [odds ratio (OR) 4.006], male gender (OR 3.507) and age 50 years (OR 2.653) were
the independent risk factors for influenza A viral pneumonia [33]. Moreover, chronic lung dis-
eases, such as bronchial asthma and chronic obstructive pulmonary disease, are well-known
risk factors for viral infections [34, 35]. In this study, the proportion of male was similar and
the patients with CAP were younger. Therefore, male gender and age might not be the reason.
Patients with CAP had a higher prevalence of chronic lung disease than did patients with
HCAP. Therefore, the CAP group may have had a higher chance of infection by respiratory
viruses, especially influenza. Furthermore, more than half of the HCAP patients (58.9%) were
Fig 3. Monthly distribution of each respiratory virus. The x-axis shows each month and the y-axis shows the
number of observed pneumonia events. (upper panel: all CAP and HCAP patients, middle panel: CAP patients only;
and lower panel: HCAP patients only).
https://doi.org/10.1371/journal.pone.0192893.g003
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hospitalized for 2 or more days in the 90 days before pneumonia. Therefore, they may have
had little opportunity of coming into contact with other patients who carried respiratory
viruses [11]. Similar to previous studies [14, 17, 22, 36], influenza A was the most commonly
identified respiratory virus in CAP patients, and this was also true for the HCAP group. Inter-
estingly, more than half of the patients (63.6%) had a history of influenza vaccination. Among
them, influenza subtype H3N2 was detected in 5 (11.4%) patients and influenza A subtype
H1N1 was found in 39 (88.6%) patients. Most of the participants were elderly patients with
mean age 70.5 years. Several studies showed that vaccine efficacy against influenza was
decreased with increasing age although there were several confounding factors [37, 38]. Since
there was no available data for vaccine constituents, it is difficult to draw conclusions about
the efficacy of influenza vaccine in this study. Further studies are required to determine the
relationship between the effectiveness of influenza vaccines and age.
In this study, viral pneumonia itself was not found to affect the clinical prognosis, such as
LOS and in-hospital mortality in either group. Recent studies of CAP have shown similar
results [22, 31], and we further showed that viral infection had no significant association with
increased mortality in patients with HCAP. Contradictory to the previous studies that reported
viral–bacterial coinfection as an important risk factor for mortality in the CAP [22, 32], no sig-
nificant difference was noted in this study. Most previous studies obtained samples for PCR
via a nasopharyngeal or oropharyngeal swab [22, 39], but this may lead to false results in cases
of viral pneumonia [11, 23]. Easier access to a tertiary referral hospital, due to the healthcare
system in Korea [40], might be another reason for the similar prognosis of patients with viral–
bacterial coinfection, and viral and bacterial infections. One thing we have to mention here is
that the results of this study should be interpreted with caution, because the true bacterial pro-
file of these patients is not known. In the present study, we enrolled only the patients who did
not receive antibiotics for more than 24 hrs prior to our hospital to increase the yield of micro-
biological test. Moreover, the conventional microbiological studies, including blood culturing
and sputum or endotracheal aspirate Gram staining and culturing, were conducted before or
within 1 hr after antibiotics administration. However, we obtained low rates of bacterial detec-
tion similar to the previous studies [41–43]: bacterial pathogens were identified in 35.7% of
patients with HCAP and in 11.8% of patients with CAP. This could be the frailty of Gram
staining and culture for bacterial detection. There is a report that the use of multi-bacterial
molecular testing approach approximately doubles pathogen detection in patients with pneu-
monia [44]. Particularly, they reported that PCR detected significantly more Haemophilus
influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, Escherichia
coli, and Klebsiella pneumoniae than standard culture-based methods [44]. In this study, only
63 (26.8%) patients (24 patients with HCAP and 39 patients with CAP) were conducted PCR
for Mycoplasma pneumoniae, and two patients with CAP showed positive results. We con-
ducted this study according to our usual clinical practice and multi-bacterial PCR is currently
not available in our hospital. However, more timely and sensitive microbiological methods
like PCR might be necessary to enable early bacterial detection and pathogen-directed therapy.
In the present study, MRSA infection was the strongest predictor of in-hospital mortality,
especially in HCAP patients (OR 10.0, 95% CI 1.331–75.619, p = 0.025) after adjusting for age,
sex, BMI, smoking history, ECOG status and comorbidities. Actually, it is well known that
MRSA pneumonia results in numerous complications and high mortality rates [45]. Further-
more, residency in a long-term care facility is identified as a risk factor for MRSA rather than
hospitalization or prescription of antimicrobials in hospitals in the recent studies [46]. We
have confirmed that fact again in this study.
HCAP was removed from the updated 2016 HAP/VAP guidelines [10], because many stud-
ies have reported that HCAP patients were not infected with MDR pathogens [6–9]. However,
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in the present study, the HCAP patients showed significantly higher MDR bacterial infection
rates. We performed a multivariate analysis adjusting for age, sex, BMI, performance status
(ECOG 3), comorbidities, and pneumonia severity indexes (PSI, CURB 65 3,
qSOFA 2), and found that HCAP is the most important predictor for MDROs (OR 14.2,
95% CI 1.734–115.9, p = 0.013) unlike previous studies [6–9]. Recently, the number of elderly
patients with frequent hospital contacts has increased rapidly and many of these individuals
are residing in nursing homes or long-term care facilities, especially in Korea [47], and those
HCAP patients might be prone to MDR bacterial infection [48–50]. Such recent trends may
explain why this study has shown results that are different from previous studies. However,
further studies with updated data are needed to confirm these findings.
Our study has several limitations. First, a limited number of invasive respiratory specimens
was available in this study. However, BAL is not a preferred technique, because of its invasive-
ness [3, 10], and good concordance has been found between the results of cultures of sputum
and transtracheal aspirates, particularly when good–quality sputum specimens are obtained
[27, 51, 52]. In this study, Gram staining and culturing of the expectorated sputum produced a
relatively high yield, and sputum RT-PCR showed a similar effectiveness as the BAL fluid
RT-PCR (87.5%). Second, we only included admitted patients with HCAP or CAP, and pneu-
monia patients in an outpatient setting were not included. Previous studies that included out-
patients reported that the viral pneumonia rate was as high as 36% [13], and there may be a
risk that our results underestimated the proportion of viral pneumonia. Lastly, this study was
conducted in only one tertiary referral hospital and thus may reflect this limited clinical con-
text. A prospective multicenter study of HCAP and CAP is needed to confirm out findings.
Conclusion
HCAP patients have a lower likelihood of viral infection than, and a similar viral profile and
seasonal variations to patients with CAP. Viral infection did not affect the prognosis of patients
with HCAP. Rather, multi-bacterial or MDR bacterial infection was the most important con-
cern in patients with HCAP.
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